LICART Drug Patent Profile
✉ Email this page to a colleague
When do Licart patents expire, and when can generic versions of Licart launch?
Licart is a drug marketed by Ibsa Inst Bio and is included in one NDA. There are two patents protecting this drug.
The generic ingredient in LICART is diclofenac epolamine. There are forty-seven drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the diclofenac epolamine profile page.
DrugPatentWatch® Generic Entry Outlook for Licart
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 20, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LICART?
- What are the global sales for LICART?
- What is Average Wholesale Price for LICART?
Summary for LICART
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 25 |
| Clinical Trials: | 1 |
| Patent Applications: | 103 |
| Drug Prices: | Drug price information for LICART |
| What excipients (inactive ingredients) are in LICART? | LICART excipients list |
| DailyMed Link: | LICART at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LICART
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for LICART
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| IBSA Institut Biochimique SA | Phase 3 |
Pharmacology for LICART
| Drug Class | Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors |
| Physiological Effect | Decreased Prostaglandin Production |
US Patents and Regulatory Information for LICART
LICART is protected by two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of LICART is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting LICART
Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING ACUTE PAIN DUE TO MINOR STRAINS, SPRAINS, AND CONTUSIONS USING A DICLOFENAC PATCH CONTAINING HEPARIN FOR ONCE DAILY ADMINISTRATION WHERE HEPARIN IS NOT RELEASED
Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING ACUTE PAIN DUE TO MINOR STRAINS, SPRAINS, AND CONTUSIONS USING A DICLOFENAC PATCH CONTAINING HEPARIN FOR ONCE DAILY ADMINISTRATION WHERE HEPARIN IS NOT RELEASED
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ibsa Inst Bio | LICART | diclofenac epolamine | SYSTEM;TOPICAL | 206976-001 | Dec 19, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ibsa Inst Bio | LICART | diclofenac epolamine | SYSTEM;TOPICAL | 206976-001 | Dec 19, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
